No connection

Search Results

LFWD

BEARISH
$6.57 Live
Lifeward Ltd. · NASDAQ
Target $20.0 (+204.4%)
$4.14 52W Range $18.6

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 13, 2026
Market cap
$24.87M
P/E
N/A
ROE
-146.1%
Profit margin
-90.4%
Debt/Equity
0.52
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
LFWD exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. The company is experiencing a collapse in top-line growth with revenue declining by 32.7% YoY, coupled with an unsustainable operating margin of -112.69%. Despite a low Price/Book ratio, the massive negative ROE (-146.12%) and consistent earnings misses (0/4 in the last year) suggest a failing business model. The extreme disconnect between the current price ($6.57) and the analyst target ($20.00) is not supported by any available fundamental data.

Key Strengths

Positive Gross Margin (38.25%)
Low Debt/Equity ratio (0.52) relative to sector average
Current Ratio above 1.0 (1.31)
Low Price-to-Sales ratio (1.13)
Price/Book ratio near 1.0

Key Risks

Severe revenue contraction (-32.7% YoY)
Extreme profitability decay (Profit Margin -90.38%)
Critical Piotroski F-Score (1/9) signaling high risk
Consistent earnings misses with average surprise of -70.60%
Catastrophic long-term price performance (-96% over 5 years)

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
12
Weak
Value
30
Future
5
Past
10
Health
15
Dividend
0
AI Verdict
High Risk / Speculative
Key drivers: Revenue collapse, Negative profitability, Poor deterministic health scores, Bearish technical trend
Confidence
90%
Value
30/100

Trades at a low multiple of sales, but value is eroded by negative earnings and shrinking revenue.

Positives
  • Low P/S ratio
  • P/B near 1.19
Watchpoints
  • Negative Forward P/E
  • No Graham Number available due to lack of earnings
Future
5/100

Growth metrics are deeply negative, indicating a shrinking business.

Positives
  • Year-over-year EPS growth is technically positive (less negative)
Watchpoints
  • Revenue growth -32.70%
  • Q/Q Revenue growth -32.66%
Past
10/100

Long-term historical trend is one of near-total value destruction.

Positives
No standout positives identified.
Watchpoints
  • 5Y Change: -96%
  • 1Y Change: -60.6%
  • Consistent earnings misses
Health
15/100

Piotroski score of 1/9 is a strong deterministic signal of financial instability.

Positives
  • Manageable Debt/Equity
Watchpoints
  • Piotroski F-Score 1/9
  • Quick Ratio 0.69 (Liquidity risk)
  • ROE -146.12%
Dividend
0/100

Non-dividend paying company.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • No dividend history

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$6.57
Analyst Target
$20.0
Upside/Downside
+204.4%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for LFWD and closest competitors.

Updated 2026-04-10
LFW
Lifeward Ltd.
Primary
5Y
-96.0%
3Y
-88.2%
1Y
-60.6%
6M
-26.0%
1M
-1.6%
1W
-4.2%
DAR
Daré Bioscience, Inc.
Peer
5Y
-91.0%
3Y
-85.0%
1Y
-38.6%
6M
-21.2%
1M
+15.7%
1W
-2.8%
ICC
IceCure Medical Ltd
Peer
5Y
-97.0%
3Y
-71.2%
1Y
-71.9%
6M
-62.9%
1M
-51.7%
1W
+7.7%
AYT
Aytu BioPharma, Inc.
Peer
5Y
-98.4%
3Y
-24.2%
1Y
+61.7%
6M
+2.7%
1M
+6.7%
1W
+1.5%
KYN
Kyntra Bio, Inc.
Peer
5Y
-98.6%
3Y
-98.5%
1Y
+10.3%
6M
-32.0%
1M
+0.7%
1W
+2.3%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-5.21
PEG Ratio
N/A
P/B Ratio
1.19
P/S Ratio
1.13
EV/Revenue
0.56
EV/EBITDA
-0.71
Market Cap
$24.87M

Profitability

Profit margins and return metrics

Profit Margin -90.38%
Operating Margin -112.69%
Gross Margin 38.25%
ROE -146.12%
ROA -40.97%

Growth

Revenue and earnings growth rates

Revenue Growth -32.7%
Earnings Growth N/A
Q/Q Revenue Growth -32.66%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.52
Moderate
Current Ratio
1.31
Good
Quick Ratio
0.69
Poor
Cash/Share
$1.42

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
21.4%
Op. Margin
-100.7%
Net Margin
-105.3%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
1.72x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-14
$N/A
2026-03-18
$-2.85
-163.9% surprise
2025-11-14
$-2.28
-18.8% surprise
2025-08-14
$-3.72
-29.2% surprise

Healthcare Sector Comparison

Comparing LFWD against 291 companies in the Healthcare sector (20 bullish, 99 neutral, 172 bearish)
Return on Equity (ROE)
-146.12%
This Stock
vs
-49.88%
Sector Avg
+193.0% (Excellent)
Profit Margin
-90.38%
This Stock
vs
-9.43%
Sector Avg
+858.0% (Superior)
Debt to Equity
0.52
This Stock
vs
3.74
Sector Avg
-86.1% (Less Debt)
Revenue Growth
-32.7%
This Stock
vs
80.78%
Sector Avg
-140.5% (Slower)
Current Ratio
1.31
This Stock
vs
3.72
Sector Avg
-64.7% (Weaker)

Similar Companies

Peer comparison within the same industry

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

LYNCH JEANNINE
Officer
Stock Award
2025-12-11
50,000 shares
Insider transactions can signal confidence or concerns about company prospects

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
NONE
2 analysts
HC Wainwright & Co.
2026-03-19
Maintains
Buy Buy
HC Wainwright & Co.
2025-11-18
Maintains
Buy Buy

Past News Coverage

Recent headlines mentioning LFWD from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile